In this regard, the RAC1-PAK1 pathway has been demonstrated to be involved in anti-VEGF (Bevacizumab) and anti-VEGFR (Sunitinib) drug resistance, since its inhibition lessens stem cell properties and overcomes therapy resistance in prostate cancer [28]. Here, RAC1 is linked to prostate carcinoma.